Director/PDMR Shareholding

June 30, 2016

June 30, 2016 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that Ordinary Shares (“Shares”) and American Depositary Shares (“ADSs”) in the Company, as set out below, have been acquired today for the Non-Executive Directors, being the part of their total fees that are paid in shares for the period of service from April 1 to June 30, 2016.

  Type of Security(1) Number of Shares/ADSs
Dominic Blakemore Shares 150  
Olivier Bohuon Shares 134  
William Burns Shares 190  
Gail Fosler ADSs 13  
Dr. Steven Gillis ADSs 61  
Dr. David Ginsburg ADSs 57  
Susan Kilsby ADSs 189  
Sara Mathew ADSs 54  
Anne Minto Shares 179  
Albert Stroucken ADSs 17  

 

(1) One ADS is equal to three Shares.

The Shares and ADSs were acquired on the London Stock Exchange and NASDAQ respectively at £44.6306 per Share and $182.7877 per ADS.

This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure Rules and Transparency Rules.

Oliver Strawbridge
Senior Assistant Company Secretary

For further information please contact:

Investor Relations    
Sarah Elton-Farr seltonfarr@shire.com +44 1256 894157

 

NOTES TO EDITORS

Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; a growing franchise in Oncology; and an emerging, innovative pipeline in Ophthalmics.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

www.shire.com